[
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation\" hreflang=\"en\">In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation</a>",
    "summary": "Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were concerned about the FDA’s ability to function.",
    "link": "https://www.fiercebiotech.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation",
    "published": "Nov 21, 2025 4:16pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were concerned about the FDA’s ability to function.",
    "ai_summary": "Here's the summary of the article:\n\n*   **Main finding:** Hundreds of biotech industry leaders have formally expressed significant concern to FDA Director Marty Makary regarding the agency's perceived instability and unpredictability, warning that it threatens U.S. innovation. A survey cited in the letter indicated 82% of biopharma respondents were worried about the FDA's functionality.\n*   **Key biological targets:** N/A (The article focuses on regulatory policy, not specific biological targets).\n*   **Application area:** Biotech industry regulation and innovation policy."
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fda-kicks-hiring-spree-and-new-communication-program-speed-sluggish-drug-reviews\" hreflang=\"en\"> FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process</a>",
    "summary": "The FDA is hiring more than 1,000 new employees and rolling out a pilot communication program in an effort to speed up the review of new drugs.",
    "link": "https://www.fiercebiotech.com/biotech/fda-kicks-hiring-spree-and-new-communication-program-speed-sluggish-drug-reviews",
    "published": "Nov 21, 2025 11:20am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "The FDA is hiring more than 1,000 new employees and rolling out a pilot communication program in an effort to speed up the review of new drugs.",
    "ai_summary": "Here's the summary:\n\n*   **Main finding:** The FDA is taking significant steps, including hiring over 1,000 new staff and implementing a pilot communication program, to accelerate the review process for new drugs.\n*   **Key biological targets (genes, proteins, pathways):** None mentioned.\n*   **Application area (diagnostics, therapeutics, biotech tools, etc.):** Improving the regulatory approval process for therapeutics."
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chutes-ladders-gilead-abruptly-parts-ways-general-counsel\" hreflang=\"en\">Chutes &amp; Ladders—Gilead abruptly parts ways with general counsel</a>",
    "summary": "Gilead’s general counsel and EVP of corporate affairs Deborah Telman will hang up the gloves by Dec. 5, the company announced in a brief filing Nov. 15. Gilead didn’t offer any explanation for Telman’s departure, plainly stating that the executive’s employment will “terminate later in the month.”",
    "link": "https://www.fiercebiotech.com/biotech/chutes-ladders-gilead-abruptly-parts-ways-general-counsel",
    "published": "Nov 20, 2025 4:26pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Gilead’s general counsel and EVP of corporate affairs Deborah Telman will hang up the gloves by Dec. 5, the company announced in a brief filing Nov. 15. Gilead didn’t offer any explanation for Telman’s departure, plainly stating that the executive’s employment will “terminate later in the month.”",
    "ai_summary": "Here's a 3-bullet point summary:\n\n*   **Main finding**: Gilead's General Counsel and EVP of Corporate Affairs, Deborah Telman, is abruptly departing the company by December 5th, with the company offering no explanation for her departure.\n*   **Key biological targets**: Not applicable; the article focuses on corporate personnel changes, not specific biological targets, genes, proteins, or pathways.\n*   **Application area**: Corporate/business news within the biotechnology sector, specifically regarding executive leadership and human resources."
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025\" hreflang=\"en\">Fierce Biotech Layoff Tracker 2025: Applied Tx lays off 46% of staff; Ensoma makes cuts</a>",
    "summary": "As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.",
    "link": "https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025",
    "published": "Dec 23, 2024 11:52am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.",
    "ai_summary": "Here's the summary based on the provided text:\n\n*   **Main finding:** Several biotech companies, specifically Applied Tx and Ensoma, are undergoing significant staff layoffs in 2025.\n*   **Key biological targets (genes, proteins, pathways):** The article focuses on industry layoffs and does not mention specific biological targets, genes, proteins, or pathways.\n*   **Application area (diagnostics, therapeutics, biotech tools, etc.):** This article falls under the category of biotech industry news and finance, rather than detailing a specific scientific application area."
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/nurix-trims-workforce-pivotal-trial-lead-btk-degrader-kicks\" hreflang=\"en\">Nurix trims workforce as pivotal trial for lead BTK degrader kicks off</a>",
    "summary": "Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset.",
    "link": "https://www.fiercebiotech.com/biotech/nurix-trims-workforce-pivotal-trial-lead-btk-degrader-kicks",
    "published": "Nov 20, 2025 8:42pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset.",
    "ai_summary": "Here's the summary:\n\n*   **Main finding:** Nurix Therapeutics is undergoing workforce reductions despite simultaneously launching a pivotal Phase 2 trial for its lead cancer asset.\n*   **Key biological targets:** Bruton's Tyrosine Kinase (BTK), as the therapeutic is described as a \"BTK degrader.\"\n*   **Application area:** Therapeutics, specifically for cancer treatment."
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/contineums-jj-partnered-ms-drug-fails-improve-vision-phase-2\" hreflang=\"en\">Contineum's J&amp;J-partnered MS drug fails to improve vision in phase 2</a>",
    "summary": "Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.",
    "link": "https://www.fiercebiotech.com/biotech/contineums-jj-partnered-ms-drug-fails-improve-vision-phase-2",
    "published": "Nov 20, 2025 5:05pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/modernas-reshaping-rolls-3-more-pipeline-purges\" hreflang=\"en\">Moderna's reshaping rolls on with 3 more pipeline purges</a>",
    "summary": "Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases.",
    "link": "https://www.fiercebiotech.com/biotech/modernas-reshaping-rolls-3-more-pipeline-purges",
    "published": "Nov 20, 2025 3:36pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/how-healthy-exchange-ideas-rfk-jr-kicked-fdas-gene-therapy-push\" hreflang=\"en\">How a 'healthy exchange of ideas' with RFK Jr. kick-started FDA's gene therapy push</a>",
    "summary": "When Tim Hunt was invited to a meeting with Robert F. Kennedy Jr. in early March, the Department of Health and Human Services secretary had only been sworn in a few weeks earlier.",
    "link": "https://www.fiercebiotech.com/biotech/how-healthy-exchange-ideas-rfk-jr-kicked-fdas-gene-therapy-push",
    "published": "Nov 18, 2025 4:37am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "When Tim Hunt was invited to a meeting with Robert F. Kennedy Jr. in early March, the Department of Health and Human Services secretary had only been sworn in a few weeks earlier.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/pfizer-details-phase-3-data-mrna-flu-vaccine\" hreflang=\"en\">Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3</a>",
    "summary": "Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.",
    "link": "https://www.fiercebiotech.com/biotech/pfizer-details-phase-3-data-mrna-flu-vaccine",
    "published": "Nov 20, 2025 11:02am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ensoma-halves-workforce-after-transitioning-genetic-medicine-clinic\" hreflang=\"en\">Ensoma halves workforce after transitioning genetic medicine to the clinic</a>",
    "summary": "Genetic medicines outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research functions.",
    "link": "https://www.fiercebiotech.com/biotech/ensoma-halves-workforce-after-transitioning-genetic-medicine-clinic",
    "published": "Nov 20, 2025 9:55am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Genetic medicines outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research functions.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/applied-lays-46-workforce-rare-disease-drug-approval-looks-out-reach\" hreflang=\"en\">Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach</a>",
    "summary": "Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half its workforce to conserve its remaining cash.",
    "link": "https://www.fiercebiotech.com/biotech/applied-lays-46-workforce-rare-disease-drug-approval-looks-out-reach",
    "published": "Nov 20, 2025 8:39am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half its workforce to conserve its remaining cash.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/aspen-enriches-parkinsons-cell-therapy-trial-kite-backed-115m-series-c\" hreflang=\"en\">Aspen enriches Parkinson's cell therapy trial with Kite-backed $115M series C</a>",
    "summary": "Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraising that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.",
    "link": "https://www.fiercebiotech.com/biotech/aspen-enriches-parkinsons-cell-therapy-trial-kite-backed-115m-series-c",
    "published": "Nov 19, 2025 5:04pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraising that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gsk-picks-flagships-quotient-profound-1st-biotech-partners-7b-pact\" hreflang=\"en\">GSK picks Flagship's Quotient, ProFound as 1st biotech partners for $7B pact</a>",
    "summary": "GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering.&nbsp;",
    "link": "https://www.fiercebiotech.com/biotech/gsk-picks-flagships-quotient-profound-1st-biotech-partners-7b-pact",
    "published": "Nov 19, 2025 3:35pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering. ",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/3b-deal-merck-kgaa-becomes-latest-big-pharma-partner-drug-discoverer-valo-health\" hreflang=\"en\">Merck KGaA links up with Flagship's Valo Health in search for Parkinson's targets, offers $3B in biobucks</a>",
    "summary": "Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The German drugmaker has inked a deal to harness Valo’s reams of human biology data to find new therapeutic targets for Parkinson’s disease, offering a potential payout eclipsing $3 billion in return.",
    "link": "https://www.fiercebiotech.com/biotech/3b-deal-merck-kgaa-becomes-latest-big-pharma-partner-drug-discoverer-valo-health",
    "published": "Nov 19, 2025 2:19pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The German drugmaker has inked a deal to harness Valo’s reams of human biology data to find new therapeutic targets for Parkinson’s disease, offering a potential payout eclipsing $3 billion in return.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25\" hreflang=\"en\">Fierce Biotech Fundraising Tracker '25: Aspen adds $115M; Solve Tx secures $120M</a>",
    "summary": "The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.",
    "link": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
    "published": "Dec 23, 2024 12:22pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/novartis-ceo-paid-top-dollar-avidity-become-leader-neuromuscular-diseases\" hreflang=\"en\">Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases'</a>",
    "summary": "Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees it—it’s never about the price tag.",
    "link": "https://www.fiercebiotech.com/biotech/novartis-ceo-paid-top-dollar-avidity-become-leader-neuromuscular-diseases",
    "published": "Nov 20, 2025 4:38am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees it—it’s never about the price tag.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/tempest-turns-factor-lifeline-trading-majority-stake-car-ts-and-ceo\" hreflang=\"en\">Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO</a>",
    "summary": "After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing the latter’s CEO on board to helm the company.",
    "link": "https://www.fiercebiotech.com/biotech/tempest-turns-factor-lifeline-trading-majority-stake-car-ts-and-ceo",
    "published": "Nov 19, 2025 11:43am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing the latter’s CEO on board to helm the company.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/celltrion-still-thinking-bigger-biosimilars-option-350m-antibody-deal\" hreflang=\"en\">Celltrion still thinking bigger than biosimilars with option for $350M antibody deal</a>",
    "summary": "Korea’s Celltrion is continuing to move beyond biosmilars, this time securing the option to use TriOar’s antibody platform in a deal potentially worth more than $350 million.",
    "link": "https://www.fiercebiotech.com/biotech/celltrion-still-thinking-bigger-biosimilars-option-350m-antibody-deal",
    "published": "Nov 19, 2025 9:14am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Korea’s Celltrion is continuing to move beyond biosmilars, this time securing the option to use TriOar’s antibody platform in a deal potentially worth more than $350 million.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/mercks-hiv-combo-matches-gileads-biktarvy-phase-3-test\" hreflang=\"en\">Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir</a>",
    "summary": "Merck &amp; Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease.",
    "link": "https://www.fiercebiotech.com/biotech/mercks-hiv-combo-matches-gileads-biktarvy-phase-3-test",
    "published": "Nov 19, 2025 8:14am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gilead-wants-us-rebuild-why-galapagos-cant-go-extinct-despite-turbulent-year\" hreflang=\"en\">'Gilead wants us to rebuild': Why Galapagos isn't allowed to go extinct after turbulent year</a>",
    "summary": "CEO Paul Stoffels has left, and his cell therapy strategy has been scrapped. So what happened to Galapagos?",
    "link": "https://www.fiercebiotech.com/biotech/gilead-wants-us-rebuild-why-galapagos-cant-go-extinct-despite-turbulent-year",
    "published": "Nov 19, 2025 6:56am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "CEO Paul Stoffels has left, and his cell therapy strategy has been scrapped. So what happened to Galapagos?",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/top-our-game-lilly-picks-philadelphia-next-spot-early-stage-biotech-lab-space\" hreflang=\"en\">'At the top of our game': Lilly picks Philadelphia as next spot for early-stage biotech lab space</a>",
    "summary": "As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening of a new Gateway Labs site, this time in Philadelphia.",
    "link": "https://www.fiercebiotech.com/biotech/top-our-game-lilly-picks-philadelphia-next-spot-early-stage-biotech-lab-space",
    "published": "Nov 18, 2025 4:47pm",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening of a new Gateway Labs site, this time in Philadelphia.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gsk-pens-50m-ltz-pact-join-big-pharma-peers-emerging-modality\" hreflang=\"en\">GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space</a>",
    "summary": "GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi. <br />",
    "link": "https://www.fiercebiotech.com/biotech/gsk-pens-50m-ltz-pact-join-big-pharma-peers-emerging-modality",
    "published": "Nov 19, 2025 4:41am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi. ",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/were-built-it-why-cytokinetics-doesnt-want-big-pharma-support-supersede-camzyos\" hreflang=\"en\">'We're built for it': Why Cytokinetics doesn't want Big Pharma support to help it supersede Camzyos</a>",
    "summary": "Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficatem. But for a biotech planning to commercialize its first drug—and without Big Pharma backing—the company's CEO Robert Blum is keeping his cool.",
    "link": "https://www.fiercebiotech.com/biotech/were-built-it-why-cytokinetics-doesnt-want-big-pharma-support-supersede-camzyos",
    "published": "Nov 17, 2025 9:43am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficatem. But for a biotech planning to commercialize its first drug—and without Big Pharma backing—the company's CEO Robert Blum is keeping his cool.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/how-biogen-returning-its-roots-west-coast-immunology-outpost\" hreflang=\"en\">How Biogen is returning to its roots with a West Coast immunology outpost</a>",
    "summary": "On its face, there wasn’t much notable about Biogen’s May 2024 acquisition of Human Immunology Biosciences (HI-Bio). A $1.15 billion upfront payment to secure a phase 3-ready monoclonal antibody is chump change in the broader world of biopharma M&amp;A, the kind of deal companies strike every day in this industry.",
    "link": "https://www.fiercebiotech.com/biotech/how-biogen-returning-its-roots-west-coast-immunology-outpost",
    "published": "Nov 18, 2025 10:46am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "On its face, there wasn’t much notable about Biogen’s May 2024 acquisition of Human Immunology Biosciences (HI-Bio). A $1.15 billion upfront payment to secure a phase 3-ready monoclonal antibody is chump change in the broader world of biopharma M&A, the kind of deal companies strike every day in this industry.",
    "ai_summary": NaN
  },
  {
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/vanda-tackles-wegovy-driven-vomiting-sparking-race-phase-3\" hreflang=\"en\">Vanda tackles Wegovy-driven vomiting, sparking race to phase 3</a>",
    "summary": "Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing up to start a phase 3 trial in the setting in the first half of next year.",
    "link": "https://www.fiercebiotech.com/biotech/vanda-tackles-wegovy-driven-vomiting-sparking-race-phase-3",
    "published": "Nov 18, 2025 10:19am",
    "source": "FierceBiotech",
    "fetched_at": "2025-11-23T21:43:13.214895",
    "summary_text": "Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing up to start a phase 3 trial in the setting in the first half of next year.",
    "ai_summary": NaN
  },
  {
    "title": "Six key obesity deals in 2025",
    "summary": "<p>Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.</p>\n<p>The post <a href=\"https://www.labiotech.eu/best-biotech/obesity-deals-2025/\">Six key obesity deals in 2025</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/best-biotech/obesity-deals-2025/",
    "published": "Fri, 21 Nov 2025 14:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.\nThe post Six key obesity deals in 2025 appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes",
    "summary": "<p>Labiotech followed one biotech heading into their first BIO-Europe partnering conference: cancer therapeutics company DISCO Pharma.</p>\n<p>The post <a href=\"https://www.labiotech.eu/podcast/how-to-succeed-at-bio-europe-disco-pharma-takes-us-behind-the-scenes/\">How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/podcast/how-to-succeed-at-bio-europe-disco-pharma-takes-us-behind-the-scenes/",
    "published": "Fri, 21 Nov 2025 09:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Labiotech followed one biotech heading into their first BIO-Europe partnering conference: cancer therapeutics company DISCO Pharma.\nThe post How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "Eight CAR-T cell therapy companies you should know about",
    "summary": "<p>Discover eight promising companies advancing their CAR-T cell therapy candidates in the clinic and have made the headlines in 2025.</p>\n<p>The post <a href=\"https://www.labiotech.eu/best-biotech/car-t-cell-therapy-companies/\">Eight CAR-T cell therapy companies you should know about</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/best-biotech/car-t-cell-therapy-companies/",
    "published": "Wed, 19 Nov 2025 14:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Discover eight promising companies advancing their CAR-T cell therapy candidates in the clinic and have made the headlines in 2025.\nThe post Eight CAR-T cell therapy companies you should know about appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "Twice the punch: The emergence of dual-payload antibody and peptide drug conjugates",
    "summary": "<p>Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics. </p>\n<p>The post <a href=\"https://www.labiotech.eu/in-depth/dual-payload-adcs-pdcs/\">Twice the punch: The emergence of dual-payload antibody and peptide drug conjugates</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/in-depth/dual-payload-adcs-pdcs/",
    "published": "Tue, 18 Nov 2025 14:03:30 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics. \nThe post Twice the punch: The emergence of dual-payload antibody and peptide drug conjugates appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "On the fast track to the clinic: early decisions in drug development",
    "summary": "<p>As biologics grow more complex, Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that cut risk and speed development.</p>\n<p>The post <a href=\"https://www.labiotech.eu/partner/from-dna-to-ind-accelerating-path-to-clinic/\">On the fast track to the clinic: early decisions in drug development</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/partner/from-dna-to-ind-accelerating-path-to-clinic/",
    "published": "Tue, 18 Nov 2025 09:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "As biologics grow more complex, Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that cut risk and speed development.\nThe post On the fast track to the clinic: early decisions in drug development appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "Precision psychiatry is the future of mental healthcare",
    "summary": "<p>Guest contributor Jennifer N. Perusini explains why psychiatry must embrace precision medicine.</p>\n<p>The post <a href=\"https://www.labiotech.eu/opinion/precision-psychiatry-future-mental-healthcare/\">Precision psychiatry is the future of mental healthcare</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/opinion/precision-psychiatry-future-mental-healthcare/",
    "published": "Mon, 17 Nov 2025 14:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Guest contributor Jennifer N. Perusini explains why psychiatry must embrace precision medicine.\nThe post Precision psychiatry is the future of mental healthcare appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "10 gene therapy companies you should know about",
    "summary": "<p>Explore 10 gene therapy companies operating within the biotech industry, as each one hopes to develop their own novel candidates. </p>\n<p>The post <a href=\"https://www.labiotech.eu/best-biotech/gene-therapy-companies/\">10 gene therapy companies you should know about</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/best-biotech/gene-therapy-companies/",
    "published": "Fri, 14 Nov 2025 14:10:17 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Explore 10 gene therapy companies operating within the biotech industry, as each one hopes to develop their own novel candidates. \nThe post 10 gene therapy companies you should know about appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology",
    "summary": "<p>Labiotech sat down with Jennifer Altomonte, co-founder of the BioEurope Startup Spotlight finalist, Fusix Biotech, who discussed Fusix’s cancer platform technology.</p>\n<p>The post <a href=\"https://www.labiotech.eu/podcast/meet-fusix-biotech-2025-bio-europe-startup-spotlight-champion-revolutionizing-oncology/\">Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/podcast/meet-fusix-biotech-2025-bio-europe-startup-spotlight-champion-revolutionizing-oncology/",
    "published": "Fri, 14 Nov 2025 09:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Labiotech sat down with Jennifer Altomonte, co-founder of the BioEurope Startup Spotlight finalist, Fusix Biotech, who discussed Fusix’s cancer platform technology.\nThe post Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "iGEM Jamboree: leap into the synthetic biology future",
    "summary": "<p>From plastic-eating plants to AI-guided therapies, iGEM 2025 reveals the innovations defining the future of synthetic biology.</p>\n<p>The post <a href=\"https://www.labiotech.eu/trends-news/igem-2025-synthetic-biology-highlights/\">iGEM Jamboree: leap into the synthetic biology future</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/trends-news/igem-2025-synthetic-biology-highlights/",
    "published": "Thu, 13 Nov 2025 14:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "From plastic-eating plants to AI-guided therapies, iGEM 2025 reveals the innovations defining the future of synthetic biology.\nThe post iGEM Jamboree: leap into the synthetic biology future appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "Biosimilars: a vital remedy for Europe’s healthcare challenges",
    "summary": "<p>Discover how biosimilars in Europe expand access, cut costs, and strengthen healthcare systems for a more sustainable future.</p>\n<p>The post <a href=\"https://www.labiotech.eu/partner/biosimilars-europe/\">Biosimilars: a vital remedy for Europe’s healthcare challenges</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/partner/biosimilars-europe/",
    "published": "Thu, 13 Nov 2025 08:30:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Discover how biosimilars in Europe expand access, cut costs, and strengthen healthcare systems for a more sustainable future.\nThe post Biosimilars: a vital remedy for Europe’s healthcare challenges appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "Swiss biotech going strong in 2025: 19 companies to put on your radar",
    "summary": "<p>Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 19 promising Swiss biotech companies.</p>\n<p>The post <a href=\"https://www.labiotech.eu/best-biotech/biotech-startups-switzerland/\">Swiss biotech going strong in 2025: 19 companies to put on your radar</a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/best-biotech/biotech-startups-switzerland/",
    "published": "Wed, 12 Nov 2025 14:10:08 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 19 promising Swiss biotech companies.\nThe post Swiss biotech going strong in 2025: 19 companies to put on your radar appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  },
  {
    "title": "New cancer cell discovery sheds light on childhood blood cancer",
    "summary": "<p>The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research.  </p>\n<p>The post <a href=\"https://www.labiotech.eu/trends-news/ztbb16-discovery-childhood-leukemia/\">New cancer cell discovery sheds light on childhood blood cancer  </a> appeared first on <a href=\"https://www.labiotech.eu\">Labiotech.eu</a>. </p>\n<p>© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.</p>",
    "link": "https://www.labiotech.eu/trends-news/ztbb16-discovery-childhood-leukemia/",
    "published": "Wed, 12 Nov 2025 10:00:00 +0000",
    "source": "Labiotech.eu",
    "fetched_at": "2025-11-23T21:43:13.810659",
    "summary_text": "The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research.  \nThe post New cancer cell discovery sheds light on childhood blood cancer   appeared first on Labiotech.eu. \n© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.",
    "ai_summary": NaN
  }
]